PE20030510A1 - Indoles sustituidos - Google Patents

Indoles sustituidos

Info

Publication number
PE20030510A1
PE20030510A1 PE2002001055A PE2002001055A PE20030510A1 PE 20030510 A1 PE20030510 A1 PE 20030510A1 PE 2002001055 A PE2002001055 A PE 2002001055A PE 2002001055 A PE2002001055 A PE 2002001055A PE 20030510 A1 PE20030510 A1 PE 20030510A1
Authority
PE
Peru
Prior art keywords
aryl
heteroaryl
cycloaliphatic
aliphatic
radical
Prior art date
Application number
PE2002001055A
Other languages
English (en)
Inventor
Helmut Buschmann
Werner Englberger
Babette-Yvonne Kogel
Michael Sattlegger
Hans Schick
Michael Przewosny
Original Assignee
Gruenenthal Chemie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gruenenthal Chemie filed Critical Gruenenthal Chemie
Publication of PE20030510A1 publication Critical patent/PE20030510A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • AIDS & HIV (AREA)
  • Anesthesiology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A INDOLES SUSTITUIDOS DE FORMULA I DONDE R1, R2, R3, R4 SON RADICAL ALIFATICO, CICLOALIFATICO, H, HALOGENO, HIDROXILO; R5 ES H, RADICAL ALIFATICO, CICLOALIFATICO, ARILO, HETEROARILO, ENTRE OTROS; R6 ES COR7, TIOL, HIDROXILO, HALOGENO, CIANO, R7 ES OR8, SR8, NR8R9; R8 Y R9 SON RADICAL ALIFATICO, CICLOALIFATICO, ARILO, HETEROARILO; A ES (CH2)(1-2), HC=CH, (CH2)nCOO, (CH2)nO(CH2)pCO, ENTRE OTROS; n ES 0-3; p ES 0-1; X ES X1, X3, ENTRE OTROS; R1' ES H, RADICAL ALIFATICO, CILOALIFATICO, ARILO, HETEROARILO; R2' ES RADICAL ALIFATICO, CICLOALIFATICO, ARILO, HETEROARILO, R3' ES RADICAL ALIFATICO, CICLOALIFATICO, ARILO, HETEROARILO; R4' ES H, ARILO, HETEROARILO, R5' ES NR6'; R6' ES RADICAL ALIFATICO, CICLOALIFATICO, ARILO, HETEROARILO. SON COMPUESTOS PREFERIDOS 4,6-DIMETIL-3-{[3'-(N,N-DIMETILAMINOMETIL)-4'-HIDROXI-4'-(3"-METOXIFENIL)-CICLOHEXILAMINO]-METIL}-1H-INDOL-2-CARBOXILATO DE ETILO; 5-METIL-3-{[3'-(N,N-DIMETILAMINOMETIL)-4'-HIDROXI-4'-(3"-METOXIFENIL)-CICLOHEXILAMINO]-METIL}-1H-INDOL-2-CARBOXILATO DE METILO; ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. LOS COMPUESTOS PUEDEN SER UTILES PARA EL TRATAMIENTO DEL DOLOR CRONICO, NEUROPATICOS, ENFERMEDADES NEURODEGENERATIVAS COMO ALZHEIMER, PARKINSON, HUNTINGTON, APOPLEJIA, ISQUEMIA CEREBRAL, INFARTO CEREBRAL, EDEMA CEREBRAL, EPILEPSIA, ESQUIZOFRENIA
PE2002001055A 2001-10-29 2002-10-28 Indoles sustituidos PE20030510A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10153346A DE10153346A1 (de) 2001-10-29 2001-10-29 Substituierte Indole

Publications (1)

Publication Number Publication Date
PE20030510A1 true PE20030510A1 (es) 2003-07-26

Family

ID=7704096

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002001055A PE20030510A1 (es) 2001-10-29 2002-10-28 Indoles sustituidos

Country Status (14)

Country Link
US (1) US7217729B2 (es)
EP (1) EP1472221B1 (es)
JP (1) JP2005511566A (es)
AR (1) AR037125A1 (es)
AT (1) ATE321026T1 (es)
CA (1) CA2465236A1 (es)
DE (2) DE10153346A1 (es)
DK (1) DK1472221T3 (es)
ES (1) ES2261748T3 (es)
HU (1) HUP0402076A2 (es)
PE (1) PE20030510A1 (es)
PL (1) PL369850A1 (es)
PT (1) PT1472221E (es)
WO (1) WO2003037863A2 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005005411A1 (en) * 2003-07-04 2005-01-20 Glaxosmithkline S.P.A. Substituted indole ligands for the orl-1 receptor
DE102004036349A1 (de) * 2004-07-27 2006-03-23 Grünenthal GmbH Substituierte 3-Phenylpiperidin-Derivate
EP1676843A1 (en) * 2004-12-31 2006-07-05 Nikem Research S.R.L. Substituted indole ligands for the ORL-1 receptor
EP1873150A1 (en) * 2006-06-30 2008-01-02 Nikem Research S.R.L. Fluorinated indoleamides useful as ligands of the ORL-1 receptor
EP2134685B1 (en) 2007-04-16 2015-09-02 AbbVie Inc. 7-nonsubstituted indole derivatives as mcl-1 inhibitors
US20100204247A1 (en) * 2007-10-04 2010-08-12 Duffy Joseph L N-substituted oxindoline derivatives as calcium channel blockers
AR070398A1 (es) 2008-02-22 2010-03-31 Gruenenthal Chemie Derivados sustituidos de indol
US20170174825A1 (en) * 2014-03-18 2017-06-22 The Board Of Regents For Oklahoma State University Systems and methods for production of artificial eumelanin
DE102014221848A1 (de) * 2014-10-27 2016-04-28 Volkswagen Ag Wasserabscheider mit Steigrohr und Dichteinrichtung, sowie Brennstoffzelle mit Wasserabscheider, und Kraftfahrzeug mit Brennstoffzelle
EP3350166A4 (en) * 2015-09-16 2019-05-01 Metacrine, Inc. FARNESOID-X RECEPTOR AGONISTS AND USES THEREOF
US20230027752A1 (en) * 2019-11-06 2023-01-26 Fudan University Opioid receptor agonist, preparation method therefor and pharmaceutical use thereof
CN112759545B (zh) * 2019-11-06 2022-12-13 复旦大学 3-(二甲氨基甲基)哌啶-4-醇类衍生物及其制备方法和药物用途
CN112759587B (zh) * 2019-11-06 2022-12-30 复旦大学 3-(二甲氨基甲基)哌啶-4-醇类衍生物及其制备方法和药物用途
CN112759544B (zh) * 2019-11-06 2022-08-26 复旦大学 3-(二甲氨基甲基)哌啶-4-醇衍生物制备方法和药物用途
CN112759546B (zh) * 2019-11-06 2022-08-26 复旦大学 3-(二甲氨基甲基)哌啶-4-醇衍生物及其制备方法和药物用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB925429A (en) * 1960-04-01 1963-05-08 Irwin Neisler & Co Indole derivatives
BE610830A (es) * 1960-12-01
JPS5116677A (ja) * 1974-07-29 1976-02-10 Sumitomo Chemical Co Shinkinabuchirofuenonjudotai oyobi sonosanfukaennoseiho
CH635584A5 (en) * 1977-03-11 1983-04-15 Hoechst Ag Process for preparing novel benzoylpiperidylalkyl indoles and related compounds
US4113866A (en) * 1977-04-01 1978-09-12 The Upjohn Company Analgetic compounds, compositions and process of treatment
US5145845A (en) * 1991-05-14 1992-09-08 Warner-Lambert Co. Substituted 2-carboxylindoles having pharmaceutical activity
NZ243065A (en) * 1991-06-13 1995-07-26 Lundbeck & Co As H Piperidine derivatives and pharmaceutical compositions
GB9321221D0 (en) 1993-10-14 1993-12-01 Glaxo Spa Heterocyclic compounds
DE19525137C2 (de) 1995-07-11 2003-02-27 Gruenenthal Gmbh 6-Dimethylaminomethyl-1-phenyl-cyclohexanverbin -dungen als Zwischenprodukte zur Herstellung pharmazeutischer Wirkstoffe
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
US5922752A (en) * 1997-06-11 1999-07-13 Hoechst Marion Roussell, Inc. NMDA (n-methyl-d-aspartate) antagonists
US6632836B1 (en) * 1998-10-30 2003-10-14 Merck & Co., Inc. Carbocyclic potassium channel inhibitors
DE19963177A1 (de) * 1999-12-27 2001-07-12 Gruenenthal Gmbh Substanzbibliothek
DE19963178A1 (de) * 1999-12-27 2001-07-05 Gruenenthal Gmbh Substituierte Indol-Mannichbasen
DE10049481A1 (de) 2000-09-29 2002-05-02 Gruenenthal Gmbh Substituierte C-Cyclohexylmethylamin-Derivate
DE10135636A1 (de) 2001-07-17 2003-02-06 Gruenenthal Gmbh Substituierte 4-Aminocyclohexanole
DE10135637A1 (de) 2001-07-17 2003-02-06 Gruenenthal Gmbh Substituierte 4-Aminocyclohexanolderivate

Also Published As

Publication number Publication date
ES2261748T3 (es) 2006-11-16
DK1472221T3 (da) 2006-07-31
WO2003037863A3 (de) 2004-08-12
AR037125A1 (es) 2004-10-20
WO2003037863A2 (de) 2003-05-08
PL369850A1 (en) 2005-05-02
JP2005511566A (ja) 2005-04-28
PT1472221E (pt) 2006-08-31
US7217729B2 (en) 2007-05-15
CA2465236A1 (en) 2003-05-08
US20040225003A1 (en) 2004-11-11
EP1472221B1 (de) 2006-03-22
HUP0402076A2 (hu) 2005-02-28
DE50206164D1 (de) 2006-05-11
DE10153346A1 (de) 2004-04-22
ATE321026T1 (de) 2006-04-15
EP1472221A2 (de) 2004-11-03

Similar Documents

Publication Publication Date Title
PE20030510A1 (es) Indoles sustituidos
PE20011047A1 (es) Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas
HN2001000099A (es) Nuevos derivados del fenil-propargiileter
PE20010211A1 (es) Compuestos de tiazol y composiciones farmaceuticas para inhibir las quinasas de proteina
PE20010645A1 (es) Compuestos espiro como antagonistas de los receptores del neuropeptido y
PE20030039A1 (es) Derivados de indol con afinidad por el receptor 5-ht6
PE20020593A1 (es) Activadores de glucocinasa del tipo isoindolin-2-ona
PE20011066A1 (es) PIRIDO [2,3-d] PIRIMIDIN-2,7-DIAMINAS INHIBIDORES DE CINASAS
AR039673A1 (es) Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metodos para su aplicacion
PE20060555A1 (es) Derivados de pirrol-oxindol como moduladores del receptor de progesterona
PE20060689A1 (es) Derivados de sulfonamidas como antagonistas de receptores orexina 2
PE20040165A1 (es) Uso de analogos del benzimidazol en el tratamiento de la proliferacion celular
PE20070115A1 (es) Derivados de [1,3,5]-triazina como inhibidores de aspartil proteasas
ES2133416T3 (es) Ligandos de subtipos de receptores de dopamina.
CO5560573A2 (es) Derivados activos de amino-ftalazinona como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los contienen
AR037907A1 (es) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
ECSP024342A (es) Nuevos derivados d e fenilpropargileter
ES2154262T3 (es) Uso de compuestos macrolidos para enfermedades oculares.
AR050274A1 (es) Derivados triciclicos del indeno-pirrol como moduladores de la serotonina
PE20030718A1 (es) Lactamas como antagonistas de taquiquininas
PE34297A1 (es) Ligandos especificos del neuropeptido y1
RU2006114045A (ru) Фенил-пиперазиновые производные в качестве модуляторов мускариновых рецепторов
SE9702564D0 (sv) New compounds
CL2020002157A1 (es) Derivados de triazina para el tratamiento de enfermedades relacionadas con neurotrofinas.
PE20040267A1 (es) Tiopirimidinas e isotiazolpirimidinas inhibidoras de quinasas

Legal Events

Date Code Title Description
FC Refusal